Mesenchymal stem cell effects on T-cell effector pathways

Stem Cell Research and Therapy

Volumn 2, Issue 4, 2011, Pages

  Duffy, Michelle M ^a   Ritter, Thomas ^a   Ceredig, Rhodri ^a   Griffin, Matthew D ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; COLITIS; CYTOTOXIC T LYMPHOCYTE; DIABETES MELLITUS; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL; THERAPY EFFECT; ANIMAL; AUTOIMMUNITY; CELL COMMUNICATION; IMMUNOLOGY; IMMUNOPATHOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALIA;

CD4 ANTIGEN; CD8 ANTIGEN;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; AUTOIMMUNITY; CELL COMMUNICATION; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOMODULATION; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TH2 CELLS;

EID: 80052451886     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt75     Document Type: Review

References (53)

1. Effector and memory T-cell differentiation: implications for vaccine development. Kaech SM, Wherry EJ, Ahmed R, Nat Rev Immunol 2002 2 251 262 10.1038/nri778 12001996 (Pubitemid 37323225)
2. How diverse - CD4 effector T cells and their functions. Wan YY, Flavell RA, J Mol Cell Biol 2009 1 20 36 10.1093/jmcb/mjp001 19482777
3. T-cell mediated immunity. Janeway C, Janeway's Immunobiology New York: Garland Science, Taylor & Francis Group, Murphy K, Travers P, Walport M, 7 2008 364 368 21698045
4. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, Miller RH, Glia 2009 57 1192 1203 10.1002/glia.20841 19191336
5. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Karlsson H, Samarasinghe S, Ball LM, Sundberg B, Lankester AC, Dazzi F, Uzunel M, Rao K, Veys P, Le Blanc K, Ringdén O, Amrolia PJ, Blood 2008 112 532 541 10.1182/blood-2007-10-119370 18445691
6. Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells. Kavanagh H, Mahon BP, Allergy 2011 66 523 531 10.1111/j.1398-9995.2010.02509.x 21091718
7. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M, Gastroenterology 2009 136 978 989 10.1053/j.gastro.2008.11.041 19135996
8. Mesenchymal stromal cells: facilitators of successful transplantation? English K, French A, Wood KJ, Cell Stem Cell 2010 7 431 442 10.1016/j.stem.2010. 09.009 20887949
9. Mesenchymal stem cells: clinical applications and biological characterization. Barry FP, Murphy JM, Int J Biochem Cell Biol 2004 36 568 584 10.1016/j.biocel.2003.11.001 15010324 (Pubitemid 38324589)
10. Immunological aspects of allogeneic mesenchymal stem cell therapies. Griffin MD, Ritter T, Mahon BP, Hum Gene Ther 2010 21 1641 1655 10.1089/hum.2010.156 20718666
11. Why are MSCs therapeutic? New data: new insight. Caplan AI, J Pathol 2009 217 318 324 10.1002/path.2469 19023885
12. Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. Barry FP, Murphy JM, English K, Mahon BP, Stem Cells Dev 2005 14 252 265 10.1089/scd.2005.14.252 15969620 (Pubitemid 40885249)
13. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R, Exp Hematol 2002 30 42 48 10.1016/S0301-472X(01)00769-X 11823036 (Pubitemid 34059216)
14. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Gieseke F, Bohringer J, Bussolari R, Dominici M, Handgretinger R, Muller I, Blood 2010 116 3770 3779 10.1182/blood-2010-02-270777 20644118
15. Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. Cutler AJ, Limbani V, Girdlestone J, Navarrete CV, J Immunol 2010 185 6617 6623 10.4049/jimmunol.1002239 20980628
16. Murine bone marrow mesenchymal stem cells cause mature dendritic cells to promote T-cell tolerance. Wang Q, Sun B, Wang D, Ji Y, Kong Q, Wang G, Wang J, Zhao W, Jin L, Li H, Scand J Immunol 2008 68 607 615 10.1111/j.1365-3083.2008. 02180.x 18959624
17. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP, Clin Exp Immunol 2009 156 149 160 10.1111/j.1365-2249.2009.03874.x 19210524
18. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. Batten P, Sarathchandra P, Antoniw JW, Tay SS, Lowdell MW, Taylor PM, Yacoub MH, Tissue Eng 2006 12 2263 2273 10.1089/ten.2006.12.2263 16968166 (Pubitemid 44734984)
19. Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. Rasmusson I, Uhlin M, Le Blanc K, Levitsky V, J Leukoc Biol 2007 82 887 893 10.1189/jlb.0307140 17609339 (Pubitemid 47511049)
20. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Najar M, Raicevic G, Boufker HI, Fayyad Kazan H, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L, Cell Immunol 2010 264 171 179 10.1016/j.cellimm.2010.06.006 20619400
21. Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. Tatara R, Ozaki K, Kikuchi Y, Hatanaka K, Oh I, Meguro A, Matsu H, Sato K, Ozawa K, Cytotherapy 2011 13 686 694 10.3109/14653249.2010.542456 21171824
22. Interleukin-27 suppresses experimental autoimmune encephalomyelitis during bone marrow stromal cell treatment. Wang J, Wang G, Sun B, Li H, Mu L, Wang Q, Li G, Shi L, Jin L, Kostulas N, J Autoimmun 2008 30 222 229 10.1016/j.jaut.2007.10.001 17997278 (Pubitemid 351551502)
23. TGF-beta expression by allogeneic bone marrow stromal cells ameliorates diabetes in NOD mice through modulating the distribution of CD4+ T cell subsets. Zhao W, Wang Y, Wang D, Sun B, Wang G, Wang J, Kong Q, Wang Q, Peng H, Jin L, Li H, Cell Immunol 2008 253 23 30 10.1016/j.cellimm.2008.06.009 18675407
24. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. Ren G, Zhao X, Zhang L, Zhang J, L'Huillier A, Ling W, Roberts AI, Le AD, Shi S, Shao C, Shi Y, J Immunol 2010 184 2321 2328 10.4049/jimmunol.0902023 20130212
25. Immunomodulation of delayed-type hypersensitivity responses by mesenchymal stem cells is associated with bystander T cell apoptosis in the draining lymph node. Lim JH, Kim JS, Yoon IH, Shin JS, Nam HY, Yang SH, Kim SJ, Park CG, J Immunol 2010 185 4022 4029 10.4049/jimmunol.0902723 20802154
26. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Ge W, Jiang J, Arp J, Liu W, Garcia B, Wang H, Transplantation 2010 90 1312 1320 10.1097/TP.0b013e3181fed001 21042238
27. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, Cavinato RA, Todeschini M, Solini S, Sonzogni A, Perico N, Remuzzi G, Noris M, J Immunol 2008 181 3933 3946 18768848
28. Mesenchymal stem cell therapy: two steps forward, one step back. Ankrum J, Karp JM, Trends Mol Med 2010 16 203 209 10.1016/j.molmed.2010.02.005 20335067
29. NFAT pulls the strings during CD4+ T helper cell effector functions. Hermann-Kleiter N, Baier G, Blood 2010 115 2989 2997 10.1182/blood-2009-10- 233585 20103781
30. Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats. Aksu AE, Horibe E, Sacks J, Ikeguchi R, Breitinger J, Scozio M, Unadkat J, Feili-Hariri M, Clin Immunol 2008 127 348 358 10.1016/j.clim.2008.02.003 18387852
31. Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. Boumaza I, Srinivasan S, Witt WT, Feghali-Bostwick C, Dai Y, Garcia-Ocana A, Feili-Hariri M, J Autoimmun 2009 32 33 42 10.1016/j.jaut.2008.10.004 19062254
32. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Madec AM, Mallone R, Afonso G, Abou Mrad E, Mesnier A, Eljaafari A, Thivolet C, Diabetologia 2009 52 1391 1399 10.1007/s00125-009-1374- z 19421731
33. The origin of TH2 responses. Coffman RL, Science 2010 328 1116 1117 10.1126/science.1192009 20508120
34. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Zhou H, Guo M, Bian C, Sun Z, Yang Z, Zeng Y, Ai H, Zhao RC, Biol Blood Marrow Transplant 2010 16 403 412 10.1016/j.bbmt.2009.11.006 19925878
35. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S, Selig M, Godwin J, Law K, Placidi C, Smith RN, Capella C, Rodig S, Adra CN, Atkinson M, Sayegh MH, Abdi R, J Immunol 2009 183 993 1004 10.4049/jimmunol.0900803 19561093
36. Th17 cells: from precursors to players in inflammation and infection. Awasthi A, Kuchroo VK, Int Immunol 2009 21 489 498 10.1093/intimm/dxp021 19261692
37. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. Ghannam S, Pene J, Torcy-Moquet G, Jorgensen C, Yssel H, J Immunol 2010 185 302 312 10.4049/jimmunol.0902007 20511548
38. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A, Blood 2005 106 1755 1761 10.1182/blood-2005-04-1496 15905186 (Pubitemid 41208591)
39. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. Rafei M, Campeau PM, Aguilar-Mahecha A, Buchanan M, Williams P, Birman E, Yuan S, Young YK, Boivin MN, Forner K, Basik M, Galipeau J, J Immunol 2009 182 5994 6002 10.4049/jimmunol.0803962 19414750
40. Opposing effect of mesenchymal stem cells on Th1 and Th17 cell polarization according to the state of CD4(+) T cell activation. Carrián F, Nova E, Luz P, Apablaza F, Figueroa F, Immunol Lett 2011 135 10 16 10.1016/j.imlet.2010.09.006 20888363
41. Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: implication for multiple sclerosis. Darlington PJ, Boivin MN, Renoux C, Francois M, Galipeau J, Freedman MS, Atkins HL, Cohen JA, Solchaga L, Bar-Or A, Ann Neurol 2010 68 540 545 10.1002/ana.22065 20661924
42. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. Bouffi C, Bony C, Courties G, Jorgensen C, Nol D, PLoS ONE 2010 5 14247 10.1371/journal.pone.0014247 21151872
43. BM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDO. Kong QF, Sun B, Wang GY, Zhai DX, Mu LL, Wang DD, Wang JH, Li R, Li HL, Eur J Immunol 2009 39 800 809 10.1002/eji.200838729 19283707
44. Flk-1+ mesenchymal stem cells aggravate collagen-induced arthritis by up-regulating interleukin-6. Chen B, Hu J, Liao L, Sun Z, Han Q, Song Z, Zhao RC, Clin Exp Immunol 2010 159 292 302 10.1111/j.1365-2249.2009.04069.x 20002448
45. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Gonzalez-Rey E, Gonzalez MA, Varela N, O'Valle F, Hernandez-Cortes P, Rico L, Buscher D, Delgado M, Ann Rheum Dis 2010 69 241 248 10.1136/ard.2008.101881 19124525
46. Bone marrow-derived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T-cell expansion. Wang Y, Zhang A, Ye Z, Xie H, Zheng S, Transplant Proc 2009 41 4352 4356 10.1016/j. transproceed.2009.08.072 20005397
47. Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells. Afzali B, Mitchell P, Lechler RI, John S, Lombardi G, Clin Exp Immunol 2009 159 120 130 19912251
48. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Carrián F, Nova E, Ruiz C, Diaz F, Inostroza C, Rojo D, Monckeberg G, Figueroa FE, Lupus 2010 19 317 322 10.1177/0961203309348983 19919974
49. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Maccario R, Podest M, Moretta A, Cometa A, Comoli P, Montagna D, Daudt L, Ibatici A, Piaggio G, Pozzi S, Frassoni F, Locatelli F, Haematologica 2005 90 516 525 15820948 (Pubitemid 40592895)
50. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Rasmusson I, Ringden O, Sundberg B, Le Blanc K, Transplantation 2003 76 1208 1213 10.1097/01.TP.0000082540.43730.80 14578755 (Pubitemid 37339646)
51. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A, Haematologica 2007 92 881 888 10.3324/haematol.11240 17606437 (Pubitemid 350144234)
52. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. Patel SA, Meyer JR, Greco SJ, Corcoran KE, Bryan M, Rameshwar P, J Immunol 2010 184 5885 5894 10.4049/jimmunol.0903143 20382885
53. Phagocytosis of apoptotic cells modulates mesenchymal stem cells osteogenic differentiation to enhance IL-17 and RANKL expression on CD4+ T cells. Tso GH, Law HK, Tu W, Chan GC, Lau YL, Stem Cells 2010 28 939 954 20222014